Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959115 | 0.82 | ALDH1A1 (0.53) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL17471304 | 0.82 | ALDH1A1 (0.53) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL8510441 | 0.80 | ADRA2C (0.45) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL6008849 | 0.80 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL23380057 | 0.78 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL22756453 | 0.78 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL10330624 | 0.77 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL1746181 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| SCHEMBL13745152 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL23364791 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CAI SHAOPEI (US) | 2012-11-01 | — | — | US | disclosed |
| US-8299081-B2 | Methods for treating drug resistant cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8222413-B2 | Methods for synthesizing heterocyclic compounds | NOVARTIS AG (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215793-A1 | Methods for treating drug resistant cancer | NOVARTIS AG | 2009-08-27 | — | — | US | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7368459-B2 | Heterocyclic compounds | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070032528-A1 | Heterocyclic compounds | RENHOWE PAUL A | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | SLC6A2 189/4885SLC6A4 300/4885SLC6A3 313/4885 |
| US-20070032528-A1 | Heterocyclic compounds | SLCO4C1, SLCO2B1, SLCO1B1 | SLC6A2 324/4885SLC6A4 240/4885SLC6A3 765/4885 |
| US-20120277434-A1 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | KCNJ2, KCNQ2, KCNJ11 | SLC6A2 206/4885SLC6A4 638/4885SLC6A3 519/4885 |
| US-20110046376-A1 | METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS. | NISCH, DOHH, DNPH1 | SLC6A2 1702/4885SLC6A4 2563/4885SLC6A3 3409/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | SLC6A2 1572/4885SLC6A4 1471/4885SLC6A3 2714/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | SLC6A2 189/4885SLC6A4 300/4885SLC6A3 313/4885 |
| US-20090215793-A1 | Methods for treating drug resistant cancer | ABCC1, SLC11A2, SLC10A1 | SLC6A2 113/4885SLC6A4 1018/4885SLC6A3 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.